HPV 16/18 Test

HPV types 16 and 18 are the two highest oncogenic and persistent high-risk HPV genotypes known to cause high-grade cervical neoplasia. HPV types 16 and 18 are associated with 60% and 10% of cervical cancers, respectively, while also having the lowest clearance rates in cervical screening. (1) Numerous studies report that women infected with HPV types 16 and 18 have a significantly higher risk for developing ≥CIN3 than women infected with other high-risk types. (1, 4)

According to the 2006 Consensus Guidelines for the Management of Women with Abnormal Cervical Cancer Screening Tests, women, 30 years of age or older, with negative cervical cytology results who test positive for the presence of high-risk HPV DNA would benefit from type-specific HPV genotyping. (3,4) Studies support the validity of genotyping for HPV types 16 and 18, whether it is used as a follow-up to a high-risk HPV screening test or performed concurrently. (1, 2, 4, 5)

Eastside Pathology offers Cervista™ HPV 16/18 genotyping in combination with Cervista™ HPV HR testing on cervical specimens collected in the Cytyc ThinPrep Pap Test PreservCyt Solution. Validation is ongoing for specimens collected in TriPath Imaging SurePath Pap Collection Fluid. The test is currently performed weekly and can be ordered with the HPV HR screen or added reflexively on the same HPV HR positive sample.

Our Molecular Pathology Lab offers the latest advancements in cervical cancer screening through an HPV DNA test and HPV 16/18 genotype in addition to a liquid-based Pap test for women.

1 Khan, et al., Journal of the National Cancer Institute, Vol. 97, No. 14, July 20, 2005, pg. 1078
2 Wright, Massad, Dunton, Spitzer, Wilkinson, Solomon (American Society for Colposcopy and Cervical
Pathology): American Journal of Obstetrics & Gynecology, October 2007, pg. 353
3 American Society for Colposcopy and Cervical Pathology website: www.asccp.org, 2008.
4 Meijer, et al., Gynecologic Oncology (103), 2006, pg. 13
5 Clinical and analytical data on file, Hologic, Inc.